55.28
price down icon1.06%   -0.59
after-market After Hours: 55.28
loading
Janux Therapeutics Inc stock is traded at $55.28, with a volume of 446.10K. It is down -1.06% in the last 24 hours and up +22.79% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$55.87
Open:
$55.46
24h Volume:
446.10K
Relative Volume:
0.77
Market Cap:
$2.88B
Revenue:
$15.13M
Net Income/Loss:
$-44.05M
P/E Ratio:
-33.91
EPS:
-1.63
Net Cash Flow:
$-47.75M
1W Performance:
+1.97%
1M Performance:
+22.79%
6M Performance:
-14.67%
1Y Performance:
+716.54%
1-Day Range:
Value
$54.01
$56.14
1-Week Range:
Value
$52.40
$58.06
52-Week Range:
Value
$5.65
$65.60

Janux Therapeutics Inc Stock (JANX) Company Profile

Name
Name
Janux Therapeutics Inc
Name
Phone
(858) 751-4493
Name
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Name
Employee
69
Name
Twitter
Name
Next Earnings Date
2024-08-06
Name
Latest SEC Filings
Name
JANX's Discussions on Twitter

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-06-23 Initiated Wedbush Outperform
Nov-14-22 Initiated William Blair Outperform

Janux Therapeutics Inc Stock (JANX) Latest News

pulisher
04:18 AM

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

04:18 AM
pulisher
04:09 AM

Nisa Investment Advisors LLC Increases Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat

04:09 AM
pulisher
Nov 04, 2024

Janux Therapeutics (NASDAQ:JANX) Trading Up 6.3%What's Next? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

How to Take Advantage of moves in (JANX) - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 01, 2024

Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's

Nov 01, 2024
pulisher
Nov 01, 2024

2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money

Nov 01, 2024
pulisher
Nov 01, 2024

Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Nov 01, 2024
pulisher
Oct 31, 2024

Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St

Oct 28, 2024
pulisher
Oct 27, 2024

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.

Oct 27, 2024
pulisher
Oct 26, 2024

Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 26, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World

Oct 26, 2024
pulisher
Oct 24, 2024

UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Janux therapeutics sees significant stock sale by major shareholder Jay Lichter for $178,084 - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials - openPR

Oct 24, 2024
pulisher
Oct 24, 2024

Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics - Barchart

Oct 24, 2024
pulisher
Oct 24, 2024

Janux Therapeutics stock offers upside on T cell engager platform, says UBS - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics - Benzinga

Oct 24, 2024
pulisher
Oct 24, 2024

Janux Therapeutics (NASDAQ:JANX) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

Paradigm Biocapital Advisors LP Acquires Shares in Janux Therape - GuruFocus.com

Oct 23, 2024
pulisher
Oct 22, 2024

RA Capital Management Reduces Stake in Janux Therapeutics - GuruFocus.com

Oct 22, 2024
pulisher
Oct 22, 2024

Insider Buying: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases 1,200,000 Shares of Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Ra Capital Management buys $53.7 million in Janux Therapeutics stock By Investing.com - Investing.com South Africa

Oct 22, 2024
pulisher
Oct 22, 2024

Ra Capital Management buys $53.7 million in Janux Therapeutics stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Vanguard S&P 500 Growth ETF (NYSEARCA:VOOG) Shares Sold by Cwm LLC - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 21, 2024
pulisher
Oct 18, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 1,843 Shares - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Janux therapeutics sees $23.8 million in stock sales By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

Janux therapeutics sees $23.8 million in stock sales - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

AQR Capital Management LLC Invests $215,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

10 Best Small-Cap Stocks to Buy for 2025 | Investing - U.S News & World Report Money

Oct 17, 2024
pulisher
Oct 16, 2024

Janux Therapeutics (NASDAQ:JANX) Shares Down 3.6%Time to Sell? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

How should investors view Janux Therapeutics Inc (JANX)? - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Monopar Therapeutics Expands Portfolio with New Patent Filing - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Janux Therapeutics Inc: Navigating Market Fluctuations with a 2.75B Market Cap - The InvestChronicle

Oct 16, 2024
pulisher
Oct 15, 2024

Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.6%Time to Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Prostate Cancer Clinical Trial Pipeline Experiences - GlobeNewswire

Oct 15, 2024
pulisher
Oct 14, 2024

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Janux Therapeutics Inc [JANX] Investment Appeal on the Rise - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Millennium Management LLC Purchases 11,281 Shares of DT Midstream, Inc. (NYSE:DTM) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Dimensional Fund Advisors LP Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

(JANX) Trading Signals - Stock Traders Daily

Oct 11, 2024
pulisher
Oct 11, 2024

How to interpret Janux Therapeutics Inc (JANX)’s stock chart patterns - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance

Oct 11, 2024
pulisher
Oct 09, 2024

Janux Therapeutics Inc [JANX] Stock sold by Insider Avalon Ventures XI, L.P. for $5.18 million - Knox Daily

Oct 09, 2024

Janux Therapeutics Inc Stock (JANX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):